Author / Salvador Valentino
-
Aspire Biopharma, Inc. Engages CTM Advisory, Ltd., and Receives Advisory Engagement from Spartan Capital Securities, LLC to Explore NASDAQ Listed Company Merger
HUMACAO, PR, March 20, 2024 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the engagement of CTM Advisory, Ltd. and has received an advisory engagement and expects to engage Spartan Capital Securities, LLC to manage the merger transaction. CTM Advisory, has been engaged by Aspire, to use its expertise…
-
Aspire Biopharma, Inc. Signs Pharmaceutical Development Agreement with Glatt Air Techniques, Inc.
HUMACAO, PR, January 18, 2024 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that it has organized and solidified its timeline for its contemplated 505(b) fast track FDA Trial on its initial product Instaprin. Aspire will be meeting with Glatt Air Techniques, its development and production partner team, in…